Besides inhibiting SIRT1 and PARP1, NAM has shown to inhibit the oncogenic KRAS/AKT pathway in skin and pancreatic cancers [58,130], modulate the expression of Myc oncogene in bladder cancer [74], and suppress IGF-1 in HCC [78]. Here, KRAS is linked to hepatocellular carcinoma.